OR WAIT null SECS
March 12, 2024
The European company has seen its business increase by 47% in North America.
March 11, 2024
The Alliance will receive the NSF Regional Innovation Engines Development Award and $1 million in funding.
March 08, 2024
EMA has validated two MAAs submitted by AstraZeneca and Daiichi Sankyo for datopotamab deruxtecan in two types of cancer.
The facility producer’s new innovation hub will offer manufacturing, life sciences, and infrastructure services.
EMA plans to add 10 partners to its real-world data initiative, DARWIN EU, in 2024.
March 07, 2024
Johnson & Johnson’s $2 billion acquisition of Ambrx boosts its pipeline of next-generation ADCs for cancer treatment.
FDA has published final guidance documents regarding validation and development of analytical procedures.
New plans laid out by AstraZeneca will see £650 million ($828 million) be invested into the UK.
Cellares CEO Fabian Gerlinghaus shares how an automated, closed-production platform with a small footprint can dramatically impact cost savings and scalability for cell and gene therapies.
March 06, 2024
Under a global license and collaboration agreement, AbbVie and OSE Immunotherapeutics will aim to develop OSE-230, a mAb for treating chronic inflammation.